Quick Answer
MAXCYTE, INC. reported R&D Expense of $20.82 million for fiscal year 2025.
MAXCYTE, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $20.82M | -6.3% |
| 2024 | $22.23M | -6.7% |
| 2023 | $23.82M | +22.1% |
| 2022 | $19.51M | +26.7% |
| 2021 | $15.41M | -13.1% |
| 2020 | $17.73M | +0.8% |
| 2019 | $17.59M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.32M | +0.0% | -15.2% |
| June 30, 2025 | $6.27M | +11.6% | +6.2% |
| March 31, 2025 | $5.90M | -11.6% | +11.0% |
| September 30, 2024 | $5.32M | -15.1% | -5.4% |
| June 30, 2024 | $5.62M | -0.8% | -15.9% |
| March 31, 2024 | $6.68M | +10.4% | +6.6% |
| September 30, 2023 | $6.26M | +17.6% | +10.6% |
| June 30, 2023 | $5.66M | +20.6% | -6.3% |
- MAXCYTE, INC. showed a decrease of -6.3% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, MAXCYTE, INC.’s r&d expense has grown by 18.4% (from $17.59 million to $20.82 million).
- The most recent figure is from MAXCYTE, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: